Abstract
Patients cured of a malignant germ-cell tumor are at a significantly increased relative risk (RR, 1.3-2.1) of developing a new malignancy, the most frequent second cancer being a new germ-cell cancer. The exact role of modern treatment of germ-cell malignancies as an etiological factor of a subsequent cancer has not yet been defined. The relative risk of developing a new non-germ-cell cancer, however, seems especially high after intensive cytotoxic treatment.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / blood
-
Carcinoma in Situ / blood
-
Carcinoma in Situ / epidemiology
-
Carcinoma in Situ / pathology*
-
Carcinoma in Situ / therapy
-
Combined Modality Therapy
-
Diagnosis, Differential
-
Follicle Stimulating Hormone / blood
-
Follow-Up Studies
-
Germinoma / blood
-
Germinoma / epidemiology
-
Germinoma / pathology*
-
Germinoma / therapy
-
Humans
-
Male
-
Neoplasm Invasiveness
-
Neoplasms, Second Primary / blood
-
Neoplasms, Second Primary / epidemiology
-
Neoplasms, Second Primary / pathology*
-
Neoplasms, Second Primary / therapy
-
Orchiectomy
-
Radiotherapy Dosage
-
Risk Factors
-
Testicular Neoplasms / blood
-
Testicular Neoplasms / epidemiology
-
Testicular Neoplasms / pathology*
-
Testicular Neoplasms / therapy
-
Time Factors
Substances
-
Biomarkers, Tumor
-
Follicle Stimulating Hormone